Patents by Inventor Elisia Villemure

Elisia Villemure has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF
    Publication number: 20240025919
    Abstract: Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
    Type: Application
    Filed: May 19, 2023
    Publication date: January 25, 2024
    Inventors: Matthew Leo Landry, Christian Nilewski, Michael Siu, Elisia Villemure, Yong Wang, BinQing Wei, Melissa Ann Ashley, Steven Do, Lewis John Gazzard, Samantha Alyson Green
  • HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS
    Publication number: 20230242506
    Abstract: The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
    Type: Application
    Filed: September 2, 2022
    Publication date: August 3, 2023
    Applicant: GENENTECHT, INC.
    Inventors: Jason Robert Zbieg, Elisia Villemure, Joachim Rudolph, Paul Powell Beroza, James John Crawford
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 11655245
    Abstract: The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 23, 2023
    Assignee: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • THERAPEUTIC COMPOUNDS AND METHODS
    Publication number: 20230119740
    Abstract: The invention provides a compound of formula (I): or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.
    Type: Application
    Filed: July 12, 2022
    Publication date: April 20, 2023
    Applicant: GENENTECH, INC.
    Inventors: Samantha Alyson GREEN, Jessica Marie GRANDNER, Steven Thomas STABEN, Neri AMARA, Vishva M. DIXIT, Elisia VILLEMURE
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20230121700
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: August 2, 2022
    Publication date: April 20, 2023
    Applicant: Genentech, Inc.
    Inventors: Jack Alexander TERRETT, Huifen CHEN, Lea CONSTANTINEAU-FORGET, Robin Larouche-Gauthier, Luce LÉPISSIER, Francis BEAUMIER, Martin DÉRY, Chantal GRAND-MAÎTRE, Claudio STURINO, Matthew VOLGRAF, Elisia VILLEMURE
  • THERAPEUTIC COMPOUNDS
    Publication number: 20230112485
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
    Type: Application
    Filed: August 8, 2022
    Publication date: April 13, 2023
    Applicant: Genentech, Inc.
    Inventors: Elisia VILLEMURE, Joachim RUDOLPH, Mingshuo ZENG
  • Oxadiazolones as transient receptor potential channel inhibitors
    Patent number: 10913742
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: February 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Daniel Shore, Elisia Villemure, Matthew Volgraf, Baihua Hu, Aijun Lu, Andrew Cridland, Stuart Ward, Francis Beaumier, Martin Dery, Robin Larouche-Gauthier
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20200308161
    Abstract: The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicant: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 10711004
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Brian Safina, Daniel Shore, Jack Terrett, Elisia Villemure, Matthew Volgraf, Stuart Ward, Aijun Lu, Robin Larouche-Gauthier, Francis Beaumier, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Luce Lepissier
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 10710994
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • Thiazolopyrimidinones and methods of use thereof
    Patent number: 10647731
    Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: May 12, 2020
    Assignee: Genentech, Inc.
    Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20200002340
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: September 3, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Brian SAFINA, Daniel SHORE, Jack TERRETT, Elisia VILLEMURE, Matthew VOLGRAF, Stuart WARD, Aijun LU, Robin LAROUCHE-GAUTHIER, Francis BEAUMIER, Martin DERY, Lea CONSTANTINEAU-FORGET, Chantal GRAND-MAITRE, Luce LEPISSIER
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20190284179
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: March 15, 2019
    Publication date: September 19, 2019
    Applicant: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20190284189
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 19, 2019
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Daniel SHORE, Elisia VILLEMURE, Matthew VOLGRAF, Baihua HU, Aijun LU, Andrew CRIDLAND, Stuart WARD, Francis BEAUMIER, Martin DERY, Robin LAROUCHE-GAUTHIER
  • Pyridopyrimidinones and methods of use thereof
    Patent number: 10280165
    Abstract: The invention relates to pyridopyrimidinone compounds of formula I or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined herein, as well as pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Matthew Volgraf, Yu Jiang, Elisia Villemure, Benjamin Sellers, Guosheng Wu, Aijun Lu
  • Substituted sulfonamide compounds
    Patent number: 10179782
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Elisia Villemure, Vishal Verma, Daniel Shore, Matthew Volgraf, Baihua Hu, Aijun Lu
  • THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF
    Publication number: 20180244694
    Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Application
    Filed: April 25, 2018
    Publication date: August 30, 2018
    Applicant: Genentech, Inc.
    Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
  • Thiazolopyrimidinones and methods of use thereof
    Patent number: 9988400
    Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 5, 2018
    Assignee: Genentech, Inc.
    Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
  • PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF
    Publication number: 20180127414
    Abstract: The invention relates to pyridopyrimidinone compounds of formula I or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined herein, as well as pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Application
    Filed: October 13, 2017
    Publication date: May 10, 2018
    Applicant: Genentech, Inc.
    Inventors: Matthew Volgraf, Yu Jiang, Elisia Villemure, Benjamin Sellers, Guosheng Wu, Aijun Lu
  • Inhibitors of cytomegalovirus
    Patent number: 9505775
    Abstract: Compounds of Formula (I) wherein R1, R2, R3A, R3B, Y, Z1 and Z2 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: November 29, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Thibeault, Jean Rancourt, Pierre L. Beaulieu, Anne Décor, Chantal Grand-Maitre, Cyrille Kuhn, Elisia Villemure, Oliver Hucke, Simon Surprenant, Melissa Leblanc, Jean-Eric Lacoste, Benoit Moreau, Eric Jolicoeur